Helper-inducer (CD29+CD4+) and suppressor-inducer (CD45RACD4+) T-cells have been recently renamed as memory and naive T-cells, respectively. We measured cells expressing these phenotypes in peripheral blood of 46 definite multiple sclerosis (MS) patients [32 relapsing-remitting (RR-MS), 14 secondary progressive (P-MS)] and controls. CD25+ (interleukin-2-receptor-positive) cells were also evaluated in the same groups of patients. RR-MS patients showed increased levels of CD29+CD4+ and CD25+ cells compared with controls. This finding was more evident in RR-MS patients during the attack than during the stable phase of the disease. In P-MS patients we found a reduction of CD45+CD4+ cells compared with either RR-MS patients or control subjects. Our results show that RR-MS and P-MS are characterized by two different T-cell subpopulations. This finding supports the hypothesis that during the evolution from RR-MS and P-MS changes occur in the immunological status of the patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF00856808 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Olfactory Evoked Potentials and Brain MRI Outcomes in Multiple Sclerosis Patients: A Cross-Sectional Study.
J Clin Med
December 2024
IRCCS Centro Neurolesi Bonino Pulejo, 98124 Messina, Italy.
Olfactory dysfunction (OD) is an underestimated symptom in multiple sclerosis (MS). Multiple factors may play a role in the OD reported by MS patients, such as ongoing inflammation in the central nervous system (CNS), damage to the olfactory bulbs due to demyelination, and the presence of plaques in brain areas associated with the olfactory system. Indeed, neuroimaging studies in MS have shown a clear association of the OD with the number and activity of MS-related plaques in frontal and temporal brain regions.
View Article and Find Full Text PDFRelationship Between T-helper 1 Inflammatory Biomarkers and Hematological Index Responses in Patients With Multiple Sclerosis.
Cureus
December 2024
Basic Sciences, Hawler Medical University, Erbil, IRQ.
Background Multiple sclerosis is a chronic, progressive, disabling disease associated with a high rate of infection, evidence of chronic inflammation, and a high mortality rate. Abnormalities of serum cytokines and changes in the activity of inflammatory cells were associated with relapsing-remitting multiple sclerosis (MS-RR). This study aims to introduce new inflammatory ratios derived from hematological and lipid indices as discriminators of T-helper (Th)-1/Th-2 activity in RR-MS.
View Article and Find Full Text PDFThe effects of Neurodynamic Mobilization exercises on upper extremity pain, muscle strength, and functions in patients with multiple sclerosis: A randomised controlled, single blinded study.
Mult Scler Relat Disord
December 2024
Kahramanmaras Sutcu Imam University, Faculty of Medicine, Department Of Neurology, Onikisubat, Kahramanmaras, Turkey. Electronic address:
Backround: Manual therapy techniques are available for pain management in Multiple Sclerosis (MS); however, the results of neurodynamic mobilization (NM) are not known. The aim of this study was to investigate the effects of NM exercises on pain, muscle strength and upper extremity functions in MS patients.
Methods: Patients aged between 18 and 65 years diagnosed with Relapsing Remitting (RR) MS (n = 31) according to McDonald 2010 diagnostic criteria were included in the study.
Epstein-Barr nuclear antigen 1 antibody-based indices are increased in patients with multiple sclerosis.
Mult Scler Relat Disord
December 2024
Department of Neurology, Rigshospitalet Glostrup, Glostrup, Denmark; Department of Neurology, University of Copenhagen, Denmark. Electronic address:
Article Synopsis
- Multiple sclerosis (MS) is a chronic disease of the central nervous system influenced by genetic and environmental factors, particularly Epstein-Barr virus (EBV) infection, which may play a direct role in its development.
- This study assessed whether EBV antibody levels in serum and cerebrospinal fluid (CSF) could assist in diagnosing MS by comparing levels in relapsing-remitting MS patients, optic neuritis patients, and healthy controls.
- The results showed higher EBV antibody levels in MS patients, suggesting these antibody indices could enhance current diagnostic methods for the disease.
Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.
Blood Cancer J
October 2024
University of Melbourne, St. Vincent's Hospital Melbourne, Melbourne, VIC, Australia.
[Image: see text]
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!